Business
Immunome Reports Third Quarter 2021 Financial Results
- IMM-BCP-01 Progressing Towards IND Filing - EXTON, Pa.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its
About this update from Immunome, Inc.
[{"type":"text","content":"\n- IMM-BCP-01 Progressing Towards IND Filing -\n\n EXTON, Pa.--(BUSINESS WIRE)--\nImmunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.\n\n“We made significant progress in advancing our three-antibody cocktail to combat SARS-CoV-2, IMM-BCP-01, reporting additional activity against emerging variants, Lambda and Delta Plus. We now have demonstrated compelling neutralizing activity of IMM-BCP-01 in all of the variants of concern, as identified by the CDC, and look forward to submitting our IND this quarter and reporting topline data in the first half of 2022,” commented Purnanand Sarma, Ph.D., President and CEO of Immunome. “We continue to advance IMM-ONC-01, our novel innate immune checkpoint that targets IL-38, towards an IND submission that we expect in early 2022.”\n\nThird Quarter and Subsequent Highlights\n\n\nDemonstrated Potent Neutralization Activity of IMM-BCP-01 Against SARS-CoV-2 Lambda and Delta Plus Variants. In September 2021, Immunome announced that its three-antibody cocktail (IMM-BCP-01) has demonstrated robust neutralizing activity against SARS-CoV-2 Lambda (C.37) and Delta AY.1/2 (Delta Plus) variants. Furthermore, IMM-BCP-01 has been shown to neutralize all of the Centers for Disease Control (CDC) variants of concern in preclinical testing*.\n\n\n\nPresented Data on Anti-IL38 Antibody Program at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference. In October 2021, Immunome presented an oral presentation of its anti-IL-38 monoclonal antibody that demonstrated the mAb inhibits tumor growth in two different murine syngeneic tumor models and induces protection following implantation of secondary tumors. Additionally, Immunome’s mAb binds to human IL-38 while inhibiting binding to its putative receptors, IL1RAPL1 and IL-36R, as well as inhibiting IL-38-mediated suppression of myeloid cell activity in vitro.\n\n\n\nSubmitted Preclinical Research of IMM-BCP-01 Against SARS-CoV-2 for Publication in bioRxiv. In October 2021, Immunome announced its submission of a preprint manuscript on its preclinical findings of its antibody cocktail, IMM-BCP-01, to bioRxiv. The manuscript detail...